An observational study in Pregnancy Related, sponsored by Ipsen. Recruiting at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Ipsen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study will include participants who were exposed to at least one dose of elafibranor either within the three weeks before conception or at any time during pregnancy (based on estimated last menstrual period [LMP]).
Information will be collected from participants, their healthcare providers, published studies, and safety databases. Reports of pregnancy linked to elafibranor from clinical trials, spontaneous reports, or literature will also be included, with steps taken to avoid duplicates.
The study begins once the first participant is enrolled and ends after the last mother and child data are collected. It is planned to run for about 10 years, with infant follow-up lasting up to 2 years, for a maximum total duration of 12 years and 9 months.
The program is strictly observational. All medical care, visit schedules, and treatment decisions remain with healthcare providers. Only routine medical record data will be collected, and no extra tests or procedures are required.
Participation is voluntary, and written informed consent will be obtained before enrollment.
592 studies on the registry are indexed under Rare Diseases; 125 are open to participants now.
This study's planned enrollment of 3 is below the median of 133 across 208 observational studies indexed under Rare Diseases.
Browse Rare Diseases studies →Ipsen is the lead sponsor of 291 studies on the registry; 19 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
Counted across the registry records on this site, refreshed daily.
The participants of this study will be of any age who are exposed to at least one dose of elafibranor at any time during pregnancy, or since 3 weeks prior to the conception (based on estimated last menstrual period [LMP])
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who are exposed to at least 1 dose of elafibranor at any time during pregnancy and/or lactation
Drug: Elafibranor
The medicinal product elafibranor is prescribed in the usual manner in accordance with the terms of the marketing authorization of the participants' country.
Prevalence of congenital malformations at birth
Time frame: At birth
Prevalence of major congenital malformations at birth
An abnormality of body structure or function that is present at birth; is of prenatal origin (i.e. birth defect); has significant medical, social, or cosmetic consequences for the affected individual; and typically requires medical intervention
Time frame: At birth
Prevalence of minor congenital malformations at birth
An anomaly or abnormality of body structure that is present at birth, is of prenatal origin (i.e. birth defect), poses no significant health problem in the neonatal period, and tends to have limited social or cosmetic consequences for the affected individual
Time frame: At birth
Prevalence of molar/ectopic pregnancy
Molar pregnancy is defined as an abnormal pregnancy that happens when a sperm fertilizes an egg that does not contain any genetic material. Ectopic pregnancy is defined as a pregnancy that occurs outside of the uterine cavity, usually in one of the fallopian tubes.
Time frame: Throughout pregnancy, an average of 9 months
Prevalence of fetal loss
A fetal loss that occurs for any reason at any time during pregnancy. This includes spontaneous abortion (SAB), stillbirth, elective or therapeutic abortion, fetal loss (type not specified).
Time frame: Throughout pregnancy, an average of 9 months
Prevalence of live birth
The birth of a living fetus at ≥ 20 gestational weeks or, if gestational age is unknown, weighing ≥ 350g.
Time frame: At birth
Prevalence rate of premature delivery
A live birth occurring at \<37 gestational weeks.
Time frame: At birth
Prevalence of infants born small for gestational age (SGA) at birth
Birth weight \<10th percentile for sex and gestational age using standard growth charts for full and preterm live-born infants.
Time frame: At birth
Prevalence of neonatal death
Time frame: Within the first 28 days of life
Prevalence infant death
Time frame: Throughout the first year of life
Prevalence of postnatal growth deficiency
Weight, length, or head circumference in \<10th percentile for sex and age using standard growth charts
Time frame: Throughout the two years of life
Prevalence of infant developmental delay
Failure to achieve the developmental milestones for chronological age, as defined by the Centers for Disease Control and Prevention (CDC)
Time frame: Throughout the two years of life
Prevalence of infant healthcare requirements and interventions not considered standard
including but not limited to: * Infant hospitalization due to serious illness * Emergency department visits * Specialist or other healthcare professional consultations * Developmental assessments and interventions * Therapeutic services * Educational support and adaptations
Time frame: Throughout the two years of life
Incidence and nature of all adverse events in pregnant participants
Time frame: Throughout pregnancy, an average of 9 months
Changes from baseline in Alkaline phosphatase (ALP)
Time frame: From the time of first elafibranor exposure throughout pregnancy and postpartum, an average of 2 years and 9 months
Changes from baseline in Bilirubin
Time frame: From the time of first elafibranor exposure throughout pregnancy and postpartum, an average of 2 years and 9 months
Changes from baseline in Alanine aminotransferase (ALT)
Time frame: From the time of first elafibranor exposure throughout pregnancy and postpartum, an average of 2 years and 9 months
Changes from baseline in Aspartate aminotransferase (AST)
Time frame: From the time of first elafibranor exposure throughout pregnancy and postpartum, an average of 2 years and 9 months
Changes from baseline in Gamma-glutamyl transferase (GGT)
Time frame: From the time of first elafibranor exposure throughout pregnancy and postpartum, an average of 2 years and 9 months
Changes from baseline in Albumin
Time frame: From the time of first elafibranor exposure throughout pregnancy and postpartum, an average of 2 years and 9 months
Changes from baselinein Bile Acids
Time frame: From the time of first elafibranor exposure throughout pregnancy and postpartum, an average of 2 years and 9 months
Changes from baseline in Creatine phosphokinase (CPK)
Time frame: From the time of first elafibranor exposure throughout pregnancy and postpartum, an average of 2 years and 9 months
Changes from baseline in Lipid Profile
Lipid profile includes total cholesterol, low density lipoproteins (LDL-C), high density lipoprotein (HDL-C), very low density lipoprotein and triglycerides
Time frame: From the time of first elafibranor exposure throughout pregnancy and postpartum, an average of 2 years and 9 months
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Data sharing details ↗ · www.ipsen.com
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jan 2039, 150 months after the start.
Of 88 observational studies under Rare Diseases, half reached primary completion within 118 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 183. This study's planned 150 months is above that.
Rare Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.